Stockscreener 앱 받기
0.7813
5.01%
0.0373
시간 외 거래:
.80
0.0187
+2.39%
전일 마감가:
$0.744
열려 있는:
$0.7411
하루 거래량:
2.69M
Relative Volume:
1.06
시가총액:
$89.77M
수익:
$257.24M
순이익/손실:
$-237.89M
주가수익비율:
-0.2353
EPS:
-3.32
순현금흐름:
$-175.17M
1주 성능:
+0.32%
1개월 성능:
-11.51%
6개월 성능:
-63.15%
1년 성능:
-63.32%
1일 변동 폭
$0.735
$0.80
1주일 범위
$0.70
$0.8855
52주 변동 폭
$0.6603
$3.70
Coherus Biosciences Inc Stock (CHRS) Company Profile
명칭
Coherus Biosciences Inc
전화
(650) 649-3530
주소
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
CHRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| CHRS | 0.7813 | 89.77M | 257.24M | -237.89M | -175.17M | -3.32 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Coherus Biosciences Inc Stock (CHRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-07-24 | 개시 | Citigroup | Buy |
| 2023-05-01 | 개시 | Truist | Buy |
| 2023-03-28 | 업그레이드 | UBS | Neutral → Buy |
| 2022-06-14 | 개시 | UBS | Neutral |
| 2022-03-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-16 | 개시 | BofA Securities | Neutral |
| 2020-04-17 | 개시 | SunTrust | Buy |
| 2019-08-13 | 개시 | Mizuho | Buy |
| 2019-08-02 | 재확인 | H.C. Wainwright | Buy |
| 2019-08-02 | 재확인 | Maxim Group | Buy |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-05-07 | 개시 | H.C. Wainwright | Buy |
| 2018-08-28 | 개시 | H.C. Wainwright | Buy |
| 2018-03-09 | 재확인 | Maxim Group | Buy |
| 2017-08-08 | 재확인 | JP Morgan | Overweight |
| 2017-06-13 | 재확인 | Maxim Group | Buy |
| 2017-05-05 | 개시 | BMO Capital Markets | Outperform |
| 2016-10-19 | 개시 | Robert W. Baird | Outperform |
| 2016-09-07 | 개시 | Maxim Group | Buy |
| 2016-07-27 | 개시 | Citigroup | Buy |
| 2016-01-20 | 개시 | Credit Suisse | Outperform |
모두보기
Coherus Biosciences Inc 주식(CHRS)의 최신 뉴스
Coherus BioSciences, Inc. (NASDAQ:CHRS) Sees Significant Growth in Short Interest - MarketBeat
Los Angeles Capital Management LLC Has $967,000 Stock Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - MarketBeat
Coherus stock rallies 19% on Q3 earnings, Udenyca production update - MSN
Robert W. Baird Has Lowered Expectations for Coherus BioSciences (NASDAQ:CHRS) Stock Price - MarketBeat
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2024 Earnings Call Transcript - Insider Monkey
Coherus BioSciences' (CHRS) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Supply Challenges - GuruFocus.com
Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... By GuruFocus - Investing.com Canada
Coherus BioSciences Reports Strong Q3 2024 Growth - TipRanks
Coherus BioSciences earnings beat by $0.15, revenue topped estimates - Investing.com Canada
Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Coherus BioSciences: Q3 Earnings Snapshot - San Antonio Express-News
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30% - Simply Wall St
Coherus BioSciences Q3 2024 Earnings Preview - MSN
CHRS stock touches 52-week low at $0.71 amid market challenges - Investing.com Australia
Coherus BioSciences Inc (CHRS) Q3 2024: Everything You Need to K - GuruFocus.com
Coherus BioSciences (CHRS) to Release Quarterly Earnings on Wednesday - MarketBeat
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024 - GlobeNewswire
Brokerages Set Coherus BioSciences, Inc. (NASDAQ:CHRS) Price Target at $7.13 - MarketBeat
CHRS stock plunges to 52-week low, hitting $0.79 By Investing.com - Investing.com Canada
CHRS stock plunges to 52-week low, hitting $0.79 - Investing.com India
Warning: CHRS is at high risk of performing badly - MSN
Such Is The Power Of Coherus Biosciences Inc (NASDAQ: CHRS) - Stocks Register
Exclusive-Russia to use ship-to-ship LNG loadings to free up ice-class tankers By Reuters - Investing.com
Coherus BioSciences (NASDAQ:CHRS) Lowered to "Hold" at StockNews.com - MarketBeat
CHRS stock touches 52-week low at $0.85 amid market challenges - Investing.com India
CHRS stock touches 52-week low at $0.85 amid market challenges By Investing.com - Investing.com South Africa
Coherus BioSciences, Inc. (NASDAQ:CHRS) Sees Significant Increase in Short Interest - MarketBeat
How should investors view Coherus Biosciences Inc (CHRS)? - US Post News
Coherus Biosciences Inc Inc. (CHRS) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
StockNews.com Upgrades Coherus BioSciences (NASDAQ:CHRS) to “Buy” - Defense World
Financial Metrics Unveiled: Coherus Biosciences Inc (CHRS)’s Key Ratios in the Spotlight - The Dwinnex
AQR Capital Management LLC Takes Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World
719,999 Shares in Coherus BioSciences, Inc. (NASDAQ:CHRS) Acquired by AQR Capital Management LLC - MarketBeat
Coherus BioSciences (NASDAQ:CHRS) Upgraded at StockNews.com - MarketBeat
CHRS stock touches 52-week low at $0.97 amid market challenges - Investing.com Canada
Coherus BioSciences Inc (CHRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Coherus Biosciences Inc (CHRS) may enjoy gains as insiders got busy in the recent days - Knox Daily
Coherus cancer drug undercuts Merck's Keytruda - MSN
Coherus Biosciences Inc (CHRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):